Phospho-YAP1 (Ser127) Antibody (YA137)
(Synonyms: YAP65, YAP1, Transcriptional coactivator YAP1, Yes-associated protein 1, Protein yorkie homolog, Yes-associated protein YAP65 homolog)Based on 1 publication(s) in Google Scholar
Phospho-YAP1 (Ser127) Antibody (YA137) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-YAP1 (Ser127).
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, IHC-P
-
Reactivity :
Human, Mouse
-
Formulation:
Supplied in 1*TBS (pH7.4), 0.05% BSA and 40% Glycerol. Preservative: 0.05% Sodium Azide.
-
Conjugation:
Non-conjugated
Publications Citing Use of MedChemExpress (MCE) Phospho-YAP1 (Ser127) Antibody (YA137)
More
Applications
| Application |
WB
WB: Western Blot
|
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
|---|---|---|
| Dilution Ratio | 1:500-1:1000 | 1:50-1:200 |
Product Details
Phospho-YAP1 (Ser127) Antibody (YA137) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-YAP1 (Ser127).
-
Host Rabbit
-
Clonality Recombinant,Monoclonal
-
Species ReactivityHuman, Mouse
-
Observed Molecular WeightObserved band size: 70 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 54 kDa
Entrez Gene: 10413 Human ; 22601 Mouse ;
SwissProt: P46937 Human ; P46938 Mouse ;
OMIM: 120433 Human
Synthetic phosphopeptide corresponding to residues surrounding Ser127 of Human YAP1.The exact sequence is proprietary to MCE.
Endogenous
Protein A affinity purified.
Non-conjugated
Phosphorylated
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in 1*TBS (pH7.4), 0.05% BSA and 40% Glycerol. Preservative: 0.05% Sodium Azide.
-
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Sci Food Agric
Ursolic acid inhibits the proliferation and migration of breast cancer cells by suppressing the hippo/YAP signaling pathway. [Abstract]2026 Jun 4. PMID: 42244112
Verification Images
-
Western blot analysis of extracts from Hela (lane 2(20μg), Hela (lane 3(40μg), using Phospho-YAP1 (Ser127) Antibody. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in TBST for 2 hour at room temperature. The primary antibody and Loading control antibody (Beta Actin, HY-P80438, 1/3000) was used in 5% BSA in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (HY-P8004/HY-P8001, 1/10,000) was used for 1 hour at room temperature.
-
Immunohistochemical analysis of paraffin-embedded mouse kidney tissue using Phospho-YAP1 (Ser127) Antibody. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked in QuickBlock for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody at 1/100 dilution in 4℃ overnight. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
-
Immunohistochemical analysis of paraffin-embedded mouse kidney tissue using Phospho-YAP1 (Ser127) Antibody. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked in QuickBlock for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody at 1/100 dilution in 4℃ overnight. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
Background
-
Function
YAP1 (Yes-associated protein 1) is a transcriptional co-activator that functions as a major downstream effector of the Hippo signaling pathway, integrating mechanical and cellular signals to regulate cell proliferation, tissue homeostasis, organ size control, and transcriptional programs mediated by TEAD transcription factors[4]. When the Hippo kinase cascade is active, LATS1/2-mediated phosphorylation restricts YAP1 nuclear localization and suppresses expression of genes involved in proliferation, migration, and epithelial-mesenchymal transition (EMT) [4]. Mechanistically, YAP1 lacks intrinsic DNA-binding activity and exerts most of its transcriptional output through TEAD family proteins, which recruit YAP1 to enhancer elements and drive target gene activation[1]. Dysregulated YAP1 signaling has been associated with cancer initiation, tumor progression, metastasis, therapy resistance, and stem cell-related phenotypes, making the Hippo-YAP1-TEAD axis an important experimental model for studying oncogenic transcriptional regulation[2][5]. Compared with its closely related paralog TAZ (WWTR1), YAP1 exhibits distinct alternatively spliced isoforms, and characterization of these isoforms has provided insight into structural and functional diversity within Hippo pathway signaling[6]. For experimental applications, disruption of the YAP1-TEAD complex is widely used to investigate YAP-dependent transcription, and verteporfin has been reported to suppress YAP-TEAD activity and serves as a commonly employed pharmacological tool in preclinical studies[3][7].
-
Subcellular Localization
Cytoplasm; Nucleus; Cell junction, tight junction; Cell membrane
-
Expression
Tissue_specificity:Increased expression has been observed in certain liver and prostate cancers. A subtype (protein level) lacking the transcriptional activation domain has been found in striatal neurons of Huntington's disease.
Induction:Induced in the hours following cyclic mechanical strain in keratinocytes -
Subunit
Part of a complex when phosphorylated that contains DSG3, PKP1, YAP1 and YWHAG; the complex is required for localization of DSG3 and YAP1 to the cell membrane in keratinocytes (PubMed:31835537). Binds to the SH3 domain of the YES kinase. Binds to WBP1 and WBP2 (PubMed:9202023). Binds, in vitro, through the WW1 domain, to neural isoforms of ENAH that contain the PPSY motif (By similarity). The phosphorylated form interacts with YWHAB (PubMed:17974916). Interacts (via WW domains) with LATS1 (via PPxY motif 2) (PubMed:18158288). Interacts with LATS2 (PubMed:18158288). Interacts with TEAD1, TEAD2, TEAD3 and TEAD4 (PubMed:18579750, PubMed:20123905, PubMed:20123908). Interacts with TP73 (PubMed:18280240). Interacts with RUNX1 (PubMed:18280240). Interacts with HCK (PubMed:17535448). Interacts (via WW domains) with PTPN14 (via PPxY motif 2); this interaction leads to the cytoplasmic sequestration of YAP1 and inhibits its transcriptional coactivator activity (PubMed:22525271). Interacts (when phosphorylated at Ser-127) with SMAD2, SMAD3 and WWTR1 (By similarity). Interacts with PRRG2 (via cytoplasmic domain) (PubMed:17502622). Interacts (via WW domains) with PRRG4 (via cytoplasmic domain) (PubMed:23873930). Interacts (phosphorylated) with CLDN18; the interaction sequesters YAP1 away from the nucleus and thereby restricts transcription of YAP1 target genes (By similarity). Interacts with SMAD1 (PubMed:21685363). Interacts with AMOTL2, the interaction is required for ubiquitination of AMOTL2 and localization of YAP1 to tight junctions (PubMed:21205866, PubMed:26598551). Interacts with AMOT isoform 1; the interaction facilitates translocation of YAP1 to the cytoplasm and tight junctions (PubMed:21205866)
-
SwissProt ID
-
Synonyms
YAP65, YAP1, Transcriptional coactivator YAP1, Yes-associated protein 1, Protein yorkie homolog, Yes-associated protein YAP65 homolog
-
Research Field
Signal Transduction
Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
User Guide for Antibodies (1077 KB)
[1]. Feng J, et al. Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer. Onco Targets Ther. 2016;9:5371-5381. [Content Brief]
[2]. Stein C, et al. YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers. PLoS Genet. 2015 Aug 21;11(8):e1005465. [Content Brief]
[3]. Szulzewsky F, et al. YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance. Dev Biol. 2021;475:205-221. [Content Brief]
[4]. UCSC.edu. DATAbase.
[5]. Battina R, et al. Targeting TEAD in cancer. Front Oncol. 2025;15:1692512.
[6]. Sudol M. YAP1 oncogene and its eight isoforms. Oncogene. 2013;32:3922.
[7]. Elisi GM, et al. Repurposing of Drugs Targeting YAP-TEAD Functions. Cancers (Basel). 2018;10(9):329.